- Report
- April 2024
- 80 Pages
Russia
From €1426EUR$1,500USD£1,198GBP
- Report
- April 2024
- 80 Pages
Saudi Arabia
From €1426EUR$1,500USD£1,198GBP
- Report
- April 2024
- 80 Pages
South Korea
From €1426EUR$1,500USD£1,198GBP
- Newsletter
- March 2025
- 12 Pages
United States
- Report
- July 2024
- 86 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- February 2024
- 89 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- August 2023
- 90 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- June 2023
- 96 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- June 2023
- 93 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- November 2022
- 1699 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- June 2022
- 207 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2022
- 35 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2022
- 112 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2022
- 64 Pages
Global
From €1901EUR$2,000USD£1,597GBP

The Melanoma Drug market is a subset of the larger Skin Cancer Drugs market. It is composed of drugs used to treat melanoma, a type of skin cancer. These drugs are typically used in combination with other treatments such as surgery, radiation, and immunotherapy. Commonly used drugs include targeted therapies, immunotherapies, and chemotherapy. Targeted therapies are designed to target specific molecules in the cancer cells, while immunotherapies are designed to boost the body's own immune system to fight the cancer. Chemotherapy is used to kill cancer cells.
The Melanoma Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Bristol-Myers Squibb, Merck, Roche, Novartis, and Pfizer. Other companies include AstraZeneca, Eli Lilly, and GlaxoSmithKline. Show Less Read more